Original Source: In Vitro Diagnostics Market

Buy Now: Market Research

GlobalData’s new report, “Belgium In Vitro Diagnostics Market Outlook to 2016″ provides key market data on the Belgium In Vitro Diagnostics (IVD) market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – clinical chemistry, genetic testing, histology and cytology, immuno chemistry, infectious immunology, microbiology culture, and haematology. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

Market size and company share data for In Vitro Diagnostics (IVD) market categories – clinical chemistry, genetic testing, histology and cytology, immuno chemistry, infectious immunology, microbiology culture, and haematology.
Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2002 to 2009, forecast forward for 7 years to 2016.
2009 company shares and distribution shares data for each of the seven market categories.
Global corporate-level profiles of key companies operating within the Belgium In Vitro Diagnostics (IVD) market.
Key players covered include Roche, Siemens Healthcare, Abbott, Beckman Coulter, Biomerieux, Ortho-Clinical Diagnostics, and Becton, Dickinson.

Reasons to buy

Develop business strategies by identifying the key market categories and segments poised for strong growth.
Develop market-entry and market expansion strategies.
Design competition strategies by identifying who-stands-where in the Belgium In Vitro Diagnostics (IVD) competitive landscape.
Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Browse complete report: Belgium In Vitro Diagnostics Market Outlook to 2016

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 What is This Report About?

3 In Vitro Diagnostics In Belgium

3.1 In Vitro Diagnostics, Market Segmentation

3.2 In Vitro Diagnostics, Belgium, Overall Revenue ($ m), 2002-2016

3.3 In Vitro Diagnostics Market, Belgium, Revenue Mix ($ m), 2009

3.4 In Vitro Diagnostics Market, Belgium, Category Contribution (%), 2009

3.5 In Vitro Diagnostics, Belgium, Company Share (2008-2009)

4 Clinical Chemistry In Belgium

4.1 Clinical Chemistry, Market Segmentation

4.2 Clinical Chemistry Market, Belgium, Revenue Mix ($ m), 2009

4.3 Clinical Chemistry Market, Belgium, Category Contribution (%), 2009

4.4 Clinical Chemistry Overall Revenue (2002-2016)

4.4.1 Clinical Chemisty Analyzers Revenue (2002-2016)

4.4.2 Urine Analysis Revenue (2002-2016)

4.5 Clinical Chemistry Distribution Share (2008-2009)

4.6 Clinical Chemistry, Belgium, Company Share (2008-2009)

5 Genetic Testing In Belgium

5.1 Genetic Testing, Market Segmentation

5.2 Genetic Testing Market, Belgium, Revenue Mix ($ m), 2009

5.3 Genetic Testing Market, Belgium, Category Contribution (%), 2009

5.4 Genetic Testing Overall Revenue (2002-2016)

5.5 Genetic Testing Distribution Share (2008-2009)

5.6 Genetic Testing, Belgium, Company Share (2008-2009)

6 Haematology In Belgium

6.1 Haematology, Market Segmentation

6.2 Haematology Market, Belgium, Revenue Mix ($ m), 2009

6.3 Haematology Market, Belgium, Category Contribution (%), 2009

6.4 Haematology Overall Revenue (2002-2016)

6.4.1 Haematology Reagents Revenue (2002-2016)

6.4.2 Immunohaematology Revenue (2002-2016)

6.4.3 Haemostasis Revenue (2002-2016)

6.4.4 Haematology Rapid Tests Revenue (2002-2016)

6.4.5 Haematology Cell Counters Revenue (2002-2016)

6.5 Haematology Distribution Share (2008-2009)

6.6 Haematology, Belgium, Company Share (2008-2009)

7 Histology And Cytology In Belgium

7.1 Histology and Cytology, Market Segmentation

7.2 Histology And Cytology Market, Belgium, Revenue Mix ($ m), 2009

7.3 Histology and Cytology Market, Belgium, Category Contribution (%), 2009

7.4 Histology And Cytology Overall Revenue (2002-2016)

7.4.1 Histology Revenue (2002-2016)

7.5 Histology And Cytology Distribution Share (2008-2009)

7.6 Histology And Cytology, Belgium, Company Share (2008-2009)

8 Immuno Chemistry In Belgium

8.1 Immuno Chemistry, Market Segmentation

8.2 Immuno Chemistry Market, Belgium, Revenue Mix ($ m), 2009

8.3 Immuno Chemistry Market, Belgium, Category Contribution (%), 2009

8.4 Immuno Chemistry Overall Revenue (2002-2016)

8.4.1 Disease Specific Immunochemistry Revenue (2002-2016)

8.4.2 Drug Related Testing Revenue (2002-2016)

8.4.3 Endocrinology Tests Revenue (2002-2016)

8.4.4 Immunochemistry Analyzers Revenue (2002-2016)

8.5 Immuno Chemistry Distribution Share (2008-2009)

8.6 Immuno Chemistry, Belgium, Company Share (2008-2009)

9 Infectious Immunology In Belgium

9.1 Infectious Immunology, Market Segmentation

9.2 Infectious Immunology Market, Belgium, Revenue Mix ($ m), 2009

9.3 Infectious Immunology Market, Belgium, Category Contribution (%), 2009

9.4 Infectious Immunology Overall Revenue (2002-2016)

9.5 Infectious Immunology Distribution Share (2008-2009)

9.6 Infectious Immunology, Belgium, Company Share (2008-2009)

10 Microbiology Culture In Belgium

10.1 Microbiology Culture, Market Segmentation

10.2 Microbiology Culture Market, Belgium, Revenue Mix ($ m), 2009

10.3 Microbiology Culture Market, Belgium, Category Contribution (%), 2009

10.4 Microbiology Culture Overall Revenue (2002-2016)

10.4.1 Microbiology Analyzers Revenue (2002-2016)

10.5 Microbiology Culture Distribution Share (2008-2009)

10.6 Microbiology Culture, Belgium, Company Share (2008-2009)

11 Overview of Key Companies in Belgium In Vitro Diagnostics Market

11.1 F. Hoffmann-La Roche Ltd.

11.1.1 Company Overview

11.1.2 Share in the Belgium In Vitro Diagnostics Market

11.2 Siemens Healthcare

11.2.1 Company Overview

11.2.2 Share in the Belgium In Vitro Diagnostics Market

11.3 Abbott Laboratories

11.3.1 Company Overview

11.3.2 Share in the Belgium In Vitro Diagnostics Market

11.4 bioMerieux S.A.

11.4.1 Company Overview

11.4.2 Share in the Belgium In Vitro Diagnostics Market

11.5 Bio-Rad Laboratories, Inc.

11.5.1 Company Overview

11.5.2 Share in the Belgium In Vitro Diagnostics Market

11.6 Beckman Coulter, Inc.

11.6.1 Company Overview

11.6.2 Share in the Belgium In Vitro Diagnostics Market

11.7 Inverness Medical Innovations, Inc.

11.7.1 Company Overview

11.8 Becton, Dickinson and Company

11.8.1 Company Overview

11.9 Hologic, Inc.

11.9.1 Company Overview

11.10 OLYMPUS CORPORATION

11.10.1 Company Overview

11.11 Sysmex Corporation

11.11.1 Company Overview

11.12 Ortho-Clinical Diagnostics Inc.

11.12.1 Company Overview

11.13 DiaSorin S.p.A

11.13.1 Company Overview

11.14 Qiagen N.V.

11.14.1 Company Overview

11.15 Gen-Probe Incorporated

11.15.1 Company Overview

11.16 Phadia AB

11.16.1 Company Overview

11.17 Innogenetics NV

11.17.1 Company Overview

11.18 BioTech Tools

11.18.1 Company Overview

11.19 Immunosource

11.19.1 Company Overview

11.20 CorisBioConcept SPRL

11.20.1 Company Overview

11.21 MabCure Inc.

11.21.1 Company Overview

12 In Vitro Diagnostics Market Pipeline Products

12.1 Clinical Chemisty Market Pipeline Products

12.2 Immuno Chemistry Market Pipeline Products

12.3 Haematology Market Pipeline Products

12.4 Infectious Immunology Market Pipeline Products

12.5 Microbiology Culture Market Pipeline Products

12.6 Histology and Cytology Market Pipeline Products

12.7 Genetic Testing Market Pipeline Products

13 Financial Deals Landscape

13.1 Partnerships

13.1.1 QIAGEN Enters Into Distribution Agreement With Celera

13.1.2 QIAGEN Enters Into Licensing Agreement With Johns Hopkins University

13.1.3 DiaGenic Enters Into Distribution Agreement With Ferrer inCode

13.1.4 OraSure Technologies Enters Into An Agreement With Roche Diagnostics

13.1.5 Inverness Medical Innovations Enters Into Distribution Agreement With Epocal

13.1.6 Radient Pharmaceuticals Enters Into An Agreement With GenWay Biotech

14 Recent Developments

14.1 Strategy and Business Planning

14.1.1 Jun 22, 2010: Ablynx Expands Into New R&D Facilities In Belgium

14.1.2 Dec 08, 2009: Genetix Expands Sales, Support And Service Organization In France And Benelux

14.2 Product News

14.2.1 May 27, 2010: Applied BioCode Receives CE Mark Certification For BioCode-1000 Analyzer

15 Appendix

15.1 Definitions of Markets Covered in the Report

15.1.1 In Vitro Diagnostics

15.2 Research Methodology

15.3 Secondary Research

15.4 Primary Research

15.5 Models

15.6 Forecasts

15.7 Expert Panels

15.8 GlobalData Consulting

15.9 Currency Conversion

15.10 Contact Us

15.11 Disclaimer